Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The actual pandemic infection related to SARS-CoV2 results in viral pneumonitis (COVID-19), that may, in the more severe cases, lead the patients to the intensive care unit (ICU). The more frequent presentation is acute respiratory distress syndrome (ARDS).
To penetrate cells, SARS-CoV2 uses Angioconvertase type 2 (ACE2) as a cellular entry receptor.
ACE2 belong to the renin-angiotensin-aldosteron system (SRAA), and ACE2 levels are directly modified when SRAA inhibitors are administred to patients, and ACE2 level increases particularely with Angiotensin II Receptor blockers (ARA2) use.
The aim of our study is to determine ACE2 level and activity in patients with SARSCoV2 infection admitted to the intensive care unit (ICU).
COVID ARA2 is a propsective cohort of patient with blood sampling at the day of admission, day 3 and day 7.
The actual pandemic infection related to SARS-CoV2 results in viral pneumonitis (COVID-19), that may, in the more severe cases, lead the patients to the intensive care unit (ICU). The more frequent presentation is acute respiratory distress syndrome (ARDS).
To penetrate cells, SARS-CoV2 uses Angioconvertase type 2 (ACE2) as a cellular entry receptor.
ACE2 belong to the renin-angiotensin-aldosteron system (SRAA), and ACE2 levels are directly modified when SRAA inhibitors are administred to patients, and ACE2 level increases particularely with Angiotensin II Receptor Blockers (ARA2) use.
The aim of our study is to determine ACE2 level and activity in patients with SARSCoV2 infection admitted to the intensive care unit (ICU).
COVID ARA2 is a propsective cohort of patient with blood sampling at the day of admission, day 3 and day 7.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| blood sampling | Biological | blood sampling at the day of admission, day 3 and day 7 |
| Measure | Description | Time Frame |
|---|---|---|
| ACE2 level change over time | ELISA test (Higher the ACE2 level, higher the virus penetrate cells) | at the day of admission, day 3 and day 7 |
| Measure | Description | Time Frame |
|---|---|---|
| ACE2 activity over time | Ratio angiotensin (1-7)/angiotensin(1/10) (Higher Ratio angiotensin (1-7)/angiotensin(1/10), higher is ACE2 activity) | at the day of admission, day 3 and day 7 |
| Mortality at day 28 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Participants :
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Pierre Asfar, MD, PhD | Contact | +33241355865 | piasfar@chu-angers.fr | |
| Julien Demiselle, MD | Contact | +33241355865 | julien.demiselle@chu-angers.fr |
| Name | Affiliation | Role |
|---|---|---|
| Pierre Asfar, MD, PhD | CHU Angers, service de médecine intensive réanimation | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Angers | Recruiting | Angers | 49933 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012128 | Respiratory Distress Syndrome |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood sample for measurement of ACE 2 level and ACE 2 activity (ratio Angiotensin(1-7)/Angiotensin(1-10))
Mortality at day 28
| day 28 |
| ARDS severity | PaO2/FiO2 ratio (ARDS is severe when <100, moderate when between 100 and 200, mild when >200) | from the day of admission to day 7 |
| Duration of mechanical ventilation | Day under mechanical ventilation | from the day of admission to day 28 |
| Need for prone positionning | Need for prone positionning | from the day of admission to day 28 |
| Need for extracorporeal membran oxygenation | Need for extracorporeal membran oxygenation | from the day of admission to day 28 |
| Use of paralytic agents | Need for use of paralytic agents | from the day of admission to day 28 |
| Need for renal replacement therapy | Need for renal replacement therapy | from the day of admission to day 28 |
| Need for vasoactive drugs (norepinephrine, dobutamine,epinephrine) | Need for vasoactive drugs | from the day of admission to day 28 |
| Sequential Organ Failure Assessment (SOFA) score | The SOFA score evaluates the severity of patients through 6 items: respiration (PaO2/FiO2 ratio); coagulation (platelets count); liver (bilirubin); Cardiovascular (hypotension); Central nervous system (coma glasgow score) and Renal (creatinine serum level). Score ranges from 0 to 24, a higher score indicates higher severity and probability of death | from the day of admission to day 7 |
| Number of session(s) of prone positionning | Number of session(s) of prone positionning | from the day of admission to day 28 |
| Duration of extracorporeal membran oxygenation treatment | Duration of extracorporeal membran oxygenation treatment | from the day of admission to day 28 |
| Type of vasoactive drugs | Several vasoactive agents may be used: norepinephrine, dobutamine, epinephrine, vasopressin analogues... | from the day of admission to day 28 |
| Duration of vasoactive treatment | Duration of vasoactive treatment | from the day of admission to day 28 |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |